Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness (PRACTICE)

January 13, 2025 updated by: University of North Carolina, Chapel Hill

Enhancing HIV-assisted Contact Tracing in Malawi Through Blended Learning: an Implementation Science Study

Having health workers assist HIV-infected persons with the recruitment and testing of their sexual contacts and biological children is an effective and efficient way of identifying additional HIV-infected persons in need of HIV treatment and HIV-uninfected persons in need of HIV prevention. However, in Malawi, a country with a generalized HIV epidemic, health workers lack the counseling and coordination skills to routinely assist their HIV-infected clients with these services. This study will determine how to help health workers to effectively and efficiently provide these services to their patients through a set of digital capacity-building tools.

Study Overview

Detailed Description

Voluntary assisted contact tracing (ACT) is an evidence-based approach that efficiently identifies persons in need of HIV treatment and prevention. Malawi, like many countries in sub-Saharan Africa, has adopted ACT policies to support its "95-95-95" targets for HIV testing, treatment, and viral suppression.

However, Malawi's ACT implementation has been poor due to deficits in health worker capacity and clinical coordination. Through preliminary work, our team has 1) developed a set of implementation strategies (theory-based health worker training and continuous quality improvement processes) that address these barriers; 2) packaged these strategies into a blended learning platform that combines digital and face-to-face modalities; and 3) field-tested the package in Malawi with promising preliminary results. In this proposal, the package will be rigorously evaluated in Malawi for implementation, service uptake, and cost-effectiveness outcomes.

Through a two-arm pragmatic cluster randomized implementation trial, the proposed research will address these gaps through three specific aims. Twenty Malawian facilities in two districts will be randomized to receive the blended learning implementation package (enhanced) versus standard implementation package (standard). In the first aim, ACT implementation outcomes will be compared between the enhanced and standard arms. Health worker fidelity to ACT procedures will be assessed through audio-recorded ACT encounters. In the second aim, HIV service uptake outcomes will be compared between the enhanced and standard arms. In the third aim, cost and cost-effectiveness outcomes will be examined.

The findings will offer important insights and innovations into how to bridge the gap between ACT research and practice, a critical step towards achieving the 95-95-95 targets.

Study Type

Interventional

Enrollment (Actual)

841

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Balaka, Malawi
        • Balaka District Hospital
      • Balaka, Malawi
        • Balaka OPD Health Centre
      • Balaka, Malawi
        • Chiendausiku Health Centre
      • Balaka, Malawi
        • Kalembo Health Centre
      • Balaka, Malawi
        • Kankao Health Centre
      • Balaka, Malawi
        • Kwitanda Health Centre
      • Balaka, Malawi
        • Mbera health Centre
      • Balaka, Malawi
        • Namanolo Health Centre
      • Balaka, Malawi
        • Namdumbo Health Centre
      • Balaka, Malawi
        • Phalula Health Centre
      • Balaka, Malawi
        • Phimbi Health Centre
      • Balaka, Malawi
        • Ulongwe Health Centre
      • Balaka, Malawi
        • Utale Health Centres
      • Machinga, Malawi
        • Machinga District Hospital
      • Machinga, Malawi
        • Chamba Dispensary
      • Machinga, Malawi
        • Chikweo Health Centre
      • Machinga, Malawi
        • Gawanani Health Centre
      • Machinga, Malawi
        • Kawinga Dispensary
      • Machinga, Malawi
        • Mahinga Health Centre
      • Machinga, Malawi
        • Mangamba Health Centre
      • Machinga, Malawi
        • Mbonechela Dispensary
      • Machinga, Malawi
        • Mkwepere Health Centre
      • Machinga, Malawi
        • Mpiri Health Centre
      • Machinga, Malawi
        • Mposa Health Centre
      • Machinga, Malawi
        • Namandanje Health Centre
      • Machinga, Malawi
        • Namanja Health Centre
      • Machinga, Malawi
        • Nayinunje Health Centre
      • Machinga, Malawi
        • Nayuchi Health Centre
      • Machinga, Malawi
        • Ngokwe Health Centre
      • Machinga, Malawi
        • Nsanama Health Centre
      • Machinga, Malawi
        • Ntaja Health Centre
      • Machinga, Malawi
        • Nthorowa Health Centre
      • Machinga, Malawi
        • Nyambi Health Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Health worker inclusion criteria:

  • 18 years of age or older
  • working full-time at one of the health facilities included in the study
  • staff in Malawi's Assisted Contact Tracing program.

Health worker exclusion criteria:

  • conditions that would compromise ability of participant to provide informed consent, undergo study procedures safely, or prevent proper conduct of study

Patient (index or contact) inclusion criteria:

->=15 years

-potential index, contact, or parent or guardian of a potential index or contact

Patient (index or contact) exclusion criteria:

  • conditions that would compromise ability of individual to provide informed consent, undergo study procedures safely, or prevent proper conduct of study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Enhanced implementation strategy
digitally guided training and continuous quality improvement
Individual training with teaching and modeling (tablet-guided, ~8 hours) Small group training with practice and feedback (tablet-guided, ~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, ~2 hours/month)
Individual training with teaching (facilitator-guided, ~2 hours) Small group practice (facilitator-guided, ~1 hour) Ongoing clinic support (facilitator-guided, ~30 minutes/month)
Active Comparator: Standard implementation strategy
standard training and clinical support
Individual training with teaching (facilitator-guided, ~2 hours) Small group practice (facilitator-guided, ~1 hour) Ongoing clinic support (facilitator-guided, ~30 minutes/month)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Index Client Fidelity Assessment
Time Frame: 1 year after training
Health care workers will be observed counseling actual index clients. The scores on the 15-item index client fidelity assessment will be compared between arms (range 0-100% with higher scores being better)
1 year after training
Contact Client Fidelity Assessment
Time Frame: 1 year after training
Health care workers will be observed counseling actual contact clients. The scores on the 15-item contact client fidelity assessment will be compared between arms (range 0-100% with higher scores being better)
1 year after training
Index Clients Who Participate in Assisted Contact Tracing
Time Frame: 1 year after training
The total number of index clients who participate in assisted contact tracing relative to the number of total potential index clients measured per facility per calendar quarter (3-month period). Each cluster contributes 4 quarters of data.
1 year after training
Contact Clients Elicited
Time Frame: 1 year after training
The number of contact clients listed by participating index clients relative to the number of total potential index clients measured per facility per calendar quarter (3-month period). Each cluster contributes 4 quarters of data.
1 year after training
HIV Self-test Kits Distributed
Time Frame: 1 year after training
The number of HIV self-test kits distributed relative to the number of total potential index clients measured per facility per calendar quarter (3-month period). Each cluster contributes 4 quarters of data.
1 year after training
Contact Clients Tested
Time Frame: 1 year after training
The number of contact clients tested relative to the number of total potential index clients measured per facility per calendar quarter (3-month period). Each cluster contributes 4 quarters of data.
1 year after training
Contact Clients Living With HIV Identified
Time Frame: 1 year after training
The number of contact clients living with HIV identified relative to the number of total potential index clients measured per facility per calendar quarter (3-month period). Each cluster contributes 4 quarters of data.
1 year after training
Incremental Cost Per Contact Tested
Time Frame: 1 year after training
Incremental cost per contact tested for HIV = Total additional cost in enhanced arm ($127,319) / total number of additional individual tested for HIV in the enhanced arm (1119). The outcome is an incremental cost effectiveness ratio. Because no additional cost was incurred in the Standard arm, the value was reported as 0.
1 year after training
Incremental Cost Per Person Living With HIV Diagnosed
Time Frame: 1 year after training
Incremental cost per contact tested for HIV = Total additional cost in enhanced arm ($127,319) / total number of additional individual diagnosed with HIV in the enhanced arm (64). The outcome is an incremental cost effectiveness ratio. Because no additional cost was incurred in the Standard arm, the value is reported as 0.
1 year after training

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Nora E Rosenberg, PhD, University of North Carolina, Chapel Hill

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2021

Primary Completion (Actual)

November 30, 2023

Study Completion (Actual)

November 30, 2023

Study Registration Dates

First Submitted

April 8, 2022

First Submitted That Met QC Criteria

April 18, 2022

First Posted (Actual)

April 25, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 13, 2025

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

At the end of the study, all data will be de-identified and shared in compliance with all regulatory bodies and NIH data sharing procedures.

IPD Sharing Time Frame

Beginning 9 months after publication and continuing through 36 months of publication

IPD Sharing Access Criteria

A repository will be selected that has policies and procedures in place that will provide data access to qualified researchers, fully consistent with NIH data sharing policies and applicable laws and regulations. The researcher will need approval form an Institutional Review Board and an executed data use/sharing agreement with University of North Carolina at Chapel Hill investigators.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Human Immunodeficiency Virus

Clinical Trials on Enhanced implementation package

Subscribe